Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study
The Effect of Lifestyle Intervention on the Risk of Cancer - A Study of Participants in the Oslo Diet and Antismoking Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The Oslo diet and antismoking study showed that a 5-year lifestyle intervention reduced the long-term risk of coronary events and mortality. The lifestyle risk factors for cancer are partly similar to those for coronary heart disease, e.g. smoking, high body weight, unfavourable diet. The investigators therefore expect that the intervention has an effect on cancer risk in the long term.
In this follow-up study, the investigators analyse the association between the intervention, and cancer incidence and mortality drawn from the Cancer Registry of Norway and the Norwegian Cause of Death Registry from the time of randomisation in 1972/3 until the end of 2015.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- participated in screening of coronary risk factors, into which all men born in 1923-1932 and living in Oslo were invited in 1972-1973
- being in the upper quartile of a coronary risk score based on blood pressure, serum total cholesterol concentration and cigarette smoking
Exclusion Criteria:
- serum total cholesterol level above 9.0 mmol per Liter
- having a healthy diet, based on a short dietary history
- self-reported cardiovascular disease or diabetes
- previous history of cancer
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control
No intervention
|
|
|
Diet and antismoking advice
Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
|
Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit.
Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages.
Smokers were advised to stop smoking.
The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of the group of cancers related to smoking, diet or body mass index
Time Frame: 43 years
|
Diagnosis of carcinoma in the oral cavity, oropharynx, esophagus, stomach, colorectum, liver and intrahepatic bile ducts, pancreas, larynx, trachea, bronchus and lung, urinary tract and thyroid gland, drawn from the Cancer Registry of Norway
|
43 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality in the group of cancers related to smoking, diet or body mass index
Time Frame: 43 years
|
Mortality in cancers in the oral cavity, oropharynx, esophagus, stomach, colorectum, liver and intrahepatic bile ducts, pancreas, larynx, trachea, bronchus and lung, urinary tract and thyroid gland, drawn from the Norwegian Cause of Death Registry
|
43 years
|
|
Cancer incidence
Time Frame: 43 years
|
Any cancer diagnosis, drawn from the Cancer Registry of Norway
|
43 years
|
|
Cancer mortality
Time Frame: 43 years
|
Mortality in any cancer, drawn from the Norwegian Cause of Death Registry
|
43 years
|
|
Incidence of gastrointestinal cancer
Time Frame: 43 years
|
Diagnosis of carcinoma in gastro-intestinal tract, drawn from the Cancer Registry of Norway
|
43 years
|
|
Incidence of lung cancer
Time Frame: 43 years
|
Diagnosis of carcinoma in lung, drawn from the Cancer Registry of Norway
|
43 years
|
|
Incidence of urinary tract cancer
Time Frame: 43 years
|
Diagnosis of carcinoma in urinary tract, drawn from the Cancer Registry of Norway
|
43 years
|
|
Incidence of prostate cancer
Time Frame: 43 years
|
Diagnosis of carcinoma in prostate, drawn from the Cancer Registry of Norway
|
43 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Paula Berstad, PhD, Cancer Registry of Norway
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016/1442
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
NCT05693831RecruitingCancer | Relapsed Cancer | Refractory Cancer
-
NCT02045381CompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer Pelvis
-
NCT07196241RecruitingCancer | Adolescent Cancer | Young Adult Cancer
-
NCT04310345CompletedAdvanced Cancer | Relapsed Cancer | Refractory Cancer
-
NCT02511821CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer
-
NCT04044430TerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer
-
NCT07224204RecruitingCancer | Adolescent Cancer | Young Adult Cancer
-
NCT05259696CompletedMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer
-
NCT03146039WithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III
-
NCT05633342RecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver Cancer
Clinical Trials on Diet and antismoking advice
-
NCT01554735CompletedQuality of Life | Inflammation | Sexual Dysfunction | Endothelial Dysfunction
-
NCT03975556CompletedHypertension | Obesity | Diabetes Mellitus, Type 2 | Dyslipidemias | Abdominal Obesity | High Triglycerides | High Blood Glucose
-
NCT06098235Recruiting
-
NCT00793832Completed
-
NCT01476436CompletedOverweight and Obesity | Type IIb Hyperlipidaemia | Hypercholesterolemia Aggravated
-
NCT00134290CompletedBody Weight | Insulin Resistance
-
NCT06089655Recruiting
-
NCT07294963RecruitingNeurocognitive Disorders | Non-Alcoholic Fatty Liver Disease
-
NCT03897972UnknownDietary Habits | Dietary Modification
-
NCT05962372RecruitingHypertension | Obesity | Diabetes Mellitus, Type 2 | Dyslipidemias | Abdominal Obesity | High Triglycerides | High Blood Glucose